BMJ Open

Examining endothelial function and carotid artery disease in patients with inflammatory bowel disease: a systematic review protocol

Hao Wu 1,2, Tingzi Hu,1 Meihua Xu,3 Hong Hao,1 Michael A Hill,4 Canxia Xu,2 Zhenguo Liu1

ABSTRACT
Introduction Patients with inflammatory bowel disease (IBD) might be at an increased risk for the development of cardiovascular disease (CVD). The present protocol is developed to review and analyse published data to determine if patients with IBD have an increased CVD burden.

Methods and analysis We will conduct a systematic review of all observational studies that examine endothelial function, arterial stiffness and carotid intima-media thickness in patients with IBD. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, and study quality will be assessed using the Newcastle-Ottawa Scale. If sufficient data are available, a meta-analysis will be conducted. The overall effect sizes will be estimated using both fixed effects models and random effects models. Statistical heterogeneity will be calculated using Higgin’s I2 test. Subgroup analyses, conditional number of studies retrieved and their sample size, will be stratified according to participant disease category or gender or disease activity.

Ethics and dissemination Formal ethics approval is not required as individual data will not be collected. The results will be disseminated through peer-reviewed publications, conference presentations and scientific news releases.

PROSPERO registration number CRD42021274093.

INTRODUCTION
Rationale Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality despite aggressive treatment of traditional risk factors.1 Systemic inflammation and endothelial cell dysfunction are considered among the key factors that are critically involved in the development and progression of CVD.1 2 3 Indeed, patients with chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and psoriasis have an increased risk of arterial and venous thromboembolic events.1 During the past decade, several studies have suggested that patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), might be at an increased risk for CVDs including coronary artery disease and arterial and venous thromboembolic events.5-9

Endothelial dysfunction is critically involved in the development and progression of atherosclerosis and related vascular diseases. Non-invasive vascular function tests such as flow-mediated dilatation (FMD), nitroglycerin-mediated dilatation (NMD) and reactive hyperemia assessed by peripheral arterial tonometry (RH-PAT) have been used to evaluate endothelial function in vivo.10 The assessment of endothelial function via brachial artery FMD has been widely used in human subjects. One of the principal mediators for FMD is endothelin-derived nitric oxide (NO).11 NMD, an index of endothelium-independent vasodilation, assessed by sublingual administration of nitroglycerine, has been used to determine if impairment in vasodilation is due to a loss in smooth-muscle cell integrity or the inability of endothelial cells to release NO.12 RH-PAT does not directly measure vasodilation, rather it measures augmentation in finger pulse pressure, which is believed to reflect microvascular dilatation through both endothelium-dependent and endothelium-independent mechanisms.13

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ This study employs a broad search strategy from multiple large databases, including PubMed, EMBASE, Cochrane library and Web of Science.
⇒ The data reporting will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
⇒ The study may be impacted by significant heterogeneity in the included studies due to differences in diagnostic tests, disease activities and the presence of traditional cardiovascular risk factors.

To cite: Wu H, Hu T, Xu M, et al. Examining endothelial function and carotid artery disease in patients with inflammatory bowel disease: a systematic review protocol. BMJ Open 2022;12:e059785. doi:10.1136/bmjopen-2021-059785

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

1School of Medicine, University of Missouri, Columbia, Missouri, USA
2Department of Gastroenterology, Central South University Third Xiangya Hospital, Changsha, China
3Department of Gastroenterology, Xiangya Hospital Central South University, Changsha, China
4Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri, USA

Correspondence to Dr Zhenguo Liu; liuzheng@health.missouri.edu

Accepted 25 May 2022

Received 01 December 2021
Arterial stiffness is a growing epidemic associated with increased risk of CVDs and assessed primarily using pulse wave velocity (PWV) and augmentation index (AIx). Increased arterial stiffness is a well-established indicator for vascular endothelial dysfunction and an independent predictor of cardiovascular events. A1x has also been shown to be associated with increased cardiovascular risk. One of the important features for arterial atherosclerosis is smooth muscle hyperplasia with increased carotid intima-media thickness (cIMT), a strong predictor of future vascular events including myocardial infarction and stroke. Although there are numerous studies evaluating endothelial function, arterial stiffness and cIMT in patients with IBD, there is no comprehensive study to systematically review and summarise the data from these individual studies.

**Objective**
The objective of this review is to systematically evaluate endothelial function, arterial stiffness and cIMT in patients with IBD.

**METHODS**

**Patients and public involvement**
No patient was involved.

**Study selection**
Observational studies (case-controlled, cross-sectional or cohort) will be included if meeting the following criteria: investigating endothelial function and arterial stiffness or their surrogate markers in patients with IBD (including patients with UC or CD) and controls; reporting measurements of cIMT in patients with IBD and control subjects; and written in English. Every effort will be made to include all the studies that meet these criteria.

**Search strategies**
A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines has been prospectively registered with PROSPERO. A comprehensive literature search and review will be conducted through the electronic databases for published studies at PubMed (1945 to present), EMBASE (1974 to present), Cochrane library (1996 to present) and Web of Science (1900 to present). We will use the Medical Subject Heading terms and keywords in all possible combinations using Boolean operators with the following search strategies: ‘Inflammatory Bowel Diseases’, ‘Inflammatory Bowel Disease’, ‘Bowel Diseases, Inflammatory’, ‘IBD’, ‘Ulcerative Colitis’, ‘Colitis, Ulcerative’, ‘Idiopathic Proctocolitis’, ‘Colitis Gravis’, ‘Inflammatory Bowel Disease, Ulcerative Colitis Type’, ‘UC’, ‘Crohn Disease’, ‘Crohn’s Disease’, ‘Crohns’s Enteritis’, ‘CD’, ‘endothelium-dependent flow-mediated dilatation’, ‘endothelium-independent flow mediated dilatation’, ‘FMD’, ‘nitroglycerin-mediated dilatation’, ‘NMD’, ‘endothelial function’, ‘peripheral arterial tonometry’, ‘PAT’, ‘reactive hyperemia’, ‘vascular stiffness’, ‘arterial stiffness’, ‘pulse wave velocity’, ‘PWV’, ‘augmentation index’, ‘AIx’, ‘intima-media thickness’ and ‘IMT’ (see online supplemental appendix 1). The references of all full-text articles will be thoroughly reviewed to identify other potentially relevant articles. All articles will be initially screened and evaluated according to their titles and abstracts. Articles describing animal studies only and non-English language articles will be excluded. Subsequently, the full articles will be evaluated by two independent reviewers (HW and TH) for eligibility. Articles will be downloaded into Endnote and any duplicates will be deleted. Data collection is anticipated to start in February of 2022 and to be completed by October 2022.

**Data extraction**
Two independent investigators (HH and MX) will screen each article and extract the data. In case of disagreement, a third investigator will be consulted (MAH). Discrepancies will be resolved by consensus. Information will be collected on study design, country of origin of the studies, sample size, major clinical and demographic variables, techniques for assessing endothelial function and arterial stiffness and IMT, as well as study outcomes associated with FMD, NMD, RH-PAT, PWV, AIx and cIMT.

**Quality assessment**
Based on the characteristics of the included studies, the methodological quality of each study will be evaluated and scored by two independent investigators (CX and ZL) using the Newcastle-Ottawa Scale, which is specifically developed to assess the quality of non-randomised observational studies. The scoring system consists of three major components: (1) the selection of the study groups; (2) the comparability of the groups; and (3) the ascertainment of either the exposure or outcome of interest for case-control or cohort studies, respectively. The total scores for each study range between 0 and 9, a higher score representing better methodological quality.

**Outcomes**
The outcomes of the review will be grouped into the following headings.

- **Endothelial function**: will include direct measurements of FMD, NMD or RH-PAT.
- **Arterial stiffness**: will be assessed by central PWV, peripheral PWV, brachial-ankle PWV and AIx.
- **Intima-media thickness**: will primarily include carotid IMT. If available, aortic or femoral arterial IMT will also be included.

**ANALYSIS**

**Descriptive analysis**
A narrative synthesis of the outcomes of the selected studies will be presented in the final review. This will include the following:
1. Type of study design, control group and sample size.
2. Major clinical and demographic variables: disease activity (active or inactive), disease extent and illness behaviour (Montreal classification), if possible.
3. Techniques for assessing endothelial function, arterial stiffness and IMT.
4. Study outcomes: this will include the change in FMD, NMD, RH-PAT, PWV, AIx and cIMT.

Statistical analysis

Meta-analysis (where possible) will be conducted to assess endothelial function, arterial stiffness and cIMT in patients with IBD. Difference between patients and controls will be calculated using the standardised mean difference (SMD) for continuous variables. These estimates and their 95% CI will be illustrated using a forest plot. The overall effect sizes will be estimated using both fixed effects models and random effects models. Statistical heterogeneity will be calculated using Higgins’s (I²) tests. Subgroup analyses, conditional on the number of studies and their sample sizes, will be stratified based on disease category (eg, UC/CD) or sex (male/female) or disease activity (eg, active/inactive).

Potential publication and small sample size bias will be assessed by visual inspections of funnel plots and Egger’s Test. To explore the effect of main factors of interest on predicting SMD, meta-regression analysis will be conducted with restricted maximum likelihood estimation method, controlling for potential confounders including disease activity, treatment and coexistence of traditional cardiovascular risk factors. All statistical analyses will be conducted using R package metafor. A p value<0.05 will be considered statistically significant for all analyses.

Contributors HW, ZL and HH conceived the idea and planned and designed the study protocol. HW wrote the first draft. TH, HH and MX planned the data extraction method, controlling for potential confounders including disease activity, treatment and coexistence of traditional cardiovascular risk factors. All statistical analyses will be conducted using R package metafor. A p value<0.05 will be considered statistically significant for all analyses.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Conflicting interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Hao Wu http://orcid.org/0000-0001-6154-9759

REFERENCES

1 Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021.
2 Ferrucci L, Fabbrini E. Inflammation and angiogenesis, cardiovascular disease, and frailty. Nat Rev Cardiol 2018;15:505–22.
3 Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363–8.
4 Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammatory mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482–9.
5 Aarestrup J, Jess T, Kobylicz C J, et al. Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals. J Crohns Colitis 2019;13:29–33.
6 Rungoe C, Basit S, Ranthe MF, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013;62:689–94.
7 Cheung JY, Lee DH, Shin DW, et al. Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study. Aliment Pharmacol Ther 2019;50:769–79.
8 Kirchgesner J, Beaugerie L, Carrat F, et al. Increased risk of acute arterial events in young patients and severely involved IBD: a nationwide French cohort study. Gut 2018;67:1261–8.
9 Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thrombembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011;60:937–43.
10 Schnabel RB, Schulz A, Wild PS, et al. Noninvasive vascular function measurement in the coronary circulation and comparison of methods. Circ Cardiovasc Imaging 2011;4:371–80.
11 Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelium-dependent flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–65.
12 Maruhashi T, Soga J, Fujimura N, et al. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol 2013;33:1401–8.
13 Rosenberry R, Nelson MD. Reactive hyperemia: a review of methods, mechanisms, and considerations. Am J Physiol Regul Integr Comp Physiol 2020;318:E605–18.
14 Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664–70.
15 Nürnberg J, Keilflogl-Scheiber A, Opazo Saez AM, et al. Augmentation index is associated with cardiovascular risk. J Hypertens 2002;20:2407–14.
16 Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459–67.
17 Ozturk K, Guler AK, Cakir M, et al. Pulse wave velocity, intima media thickness, and flow-mediated dilatation in patients with normotensive normoglycemic inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1–20.
18 Principi M, Mastrolonardo M, Sciscitano P, et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis 2013;7:e427–33.
19 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLos Med 2009;6:e1000097.
20 Wells BS, D GA, O’Connell JP, Welch V, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011.
21 Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
22 V W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010;36:1–48.